Elsubrutinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameElsubrutinib
Drug Alias NameABBV-105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAbbvie Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A